Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hematologic diseases

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,145 result(s) found for: Hematologic diseases. Displaying page 1 of 58.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-000848-34 Sponsor Protocol Number: IPl-145-23 Start Date*: 2016-09-21
    Sponsor Name:Verastem, INC
    Full Title: Long term, Continued Treatment and Follow up Study in Subjects with Hematologic Malignancies Treated with Duvelisib (IPI 145)
    Medical condition: Hematologic Malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10066481 Hematological malignancy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-010982-22 Sponsor Protocol Number: DSC/08/2357/38 Start Date*: 2009-04-20
    Sponsor Name:ITALFARMACO
    Full Title: Phase II study of the histone-deacetylase inhibitor GIVINOSTAT (ITF2357) in combination with hydroxyurea in patients with JAK2V617F positive Polycythemia Vera non-responder to hydroxyurea monotherapy
    Medical condition: Polycythemia Vera
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004851 10018847 Haematological disorders HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-003845-41 Sponsor Protocol Number: UCL/07/131 Start Date*: 2009-02-06
    Sponsor Name:University College London
    Full Title: Transplantation of umbilical cord blood (UCB) from unrelated donors (URD) in patients with haematological diseases using a reduced intensity conditioning regimen.
    Medical condition: Haematological disorders
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004851 10018847 Haematological disorders HLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-007652-34 Sponsor Protocol Number: Bismuth-PBH-2008 Start Date*: 2009-03-05
    Sponsor Name:Herlev Hospital, Dept. of haematology (L121)
    Full Title: Kan mineraltilskud med bismuth mindske toksiciteten af kemoterapi og strålebehandling? En klinisk prospektiv, dobbeltblind randomiseret undersøgelse af patienter med hæmatologiske sygdomme som modt...
    Medical condition: Malignant diseases of the blood requiring chemotherapy and/or radiation therapy of head and neck
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066481 Hematological malignancy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005524-26 Sponsor Protocol Number: GBI1406 Start Date*: 2016-07-29
    Sponsor Name:Grifols Biologicals Inc.
    Full Title: A Multicenter Phase 2 Open-Label, Single-Arm, Prospective, Interventional Study of Plasma-Derived Factor VIIIIVWF Alphanate® in Immune Tolerance Induction Therapy in Subjects with Congenital Hemoph...
    Medical condition: Inhibitors in patients with severe Congenital Haemophilia A
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004851 10018847 Haematological disorders HLT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male
    Trial protocol: ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001344-57 Sponsor Protocol Number: PENTALLO Start Date*: 2019-10-10
    Sponsor Name:GITMO GRUPPO ITALIANO PER IL TRAPIANTO DI MIDOLLO OSSEO, CELLULE STAMINALI EMOPOIETICHE E TERAPIA
    Full Title: Pentaglobin as early adjuvant treatment for febrile neutropenia in acute leukemia or allogeneic hematopoietic stem cell transplant patients colonized by carbapenem-resistant Enterobacteriaceae or P...
    Medical condition: The study will enroll consecutive adult patients suffering from acute leukemia candidate to intensive chemotherapy or patients with hematological cancers candidate to allogeneic transplant with a d...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10013120 Diseases of blood and blood-forming organs, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-011818-21 Sponsor Protocol Number: UCL/09/0128 Start Date*: 2010-06-28
    Sponsor Name:University College London [...]
    1. University College London
    2.
    Full Title: Transplantation of umbilical cord blood from unrelated donors in patients with haematological diseases using a myeloablative conditioning regimen
    Medical condition: Haematological disorders
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004851 10018847 Haematological disorders HLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004764-30 Sponsor Protocol Number: BRD11/6-N Start Date*: Information not available in EudraCT
    Sponsor Name:CHU Nantes
    Full Title: Phase 2 study of a reduced-toxicity myeloablative conditionning regimen using fludarabine and full doses of IV busulfan in pediatric patients not eligible for standard myeloablative conditioning r...
    Medical condition: Hematological malignancy
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066481 Hematological malignancy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002761-19 Sponsor Protocol Number: OP201 Start Date*: 2019-10-21
    Sponsor Name:Oncopeptides AB
    Full Title: An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL Amyloidosis Following at Least One Prior Line of Therapy
    Medical condition: Patients with AL Amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10002022 Amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) NO (Prematurely Ended) PL (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) GR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001642-18 Sponsor Protocol Number: D8230C00002 Start Date*: 2021-05-13
    Sponsor Name:AstraZeneca AB
    Full Title: A Modular Phase I/II, Open-label, Multicentre Study to Assess AZD4573 in Novel Combinations with Anti-cancer Agents in Patients with Advanced Haematological Malignancies
    Medical condition: Haematological Malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066476 Haematological malignancy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) ES (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005766-39 Sponsor Protocol Number: GS-US-313-2120 Start Date*: 2016-04-26
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: An Open Label, Roll Over Study to Provide Idelalisib to Subjects Previously Treated with the Investigational PI3Kδ Inhibitor, GS-9820
    Medical condition: Lymphoid Malignancies
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10066481 Hematological malignancy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2022-001080-27 Sponsor Protocol Number: CD45RADLIHaplo Start Date*: 2022-11-23
    Sponsor Name:University Hospital Tuebingen
    Full Title: A multi-center phase I/II trial of memory T cell donor lymphocyte infusions after transplantation of CliniMACS TCRα/β and CD19 depleted stem cell grafts from haploidentical donors for hematopoietic...
    Medical condition: Patients suffering from hematological malignancies and eligible for haploidentical allogeneic stem cell transplantation. Patients will be included prior start of conditioning for SCT. Inclusion cri...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066481 Hematological malignancy LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2016-001860-12 Sponsor Protocol Number: CMAK683X2101 Start Date*: 2017-01-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies
    Medical condition: Advanced malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    21.1 100000004864 10066481 Hematological malignancy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-001418-13 Sponsor Protocol Number: TED10893 Start Date*: 2014-11-04
    Sponsor Name:Sanofi-aventis recherche & développement
    Full Title: A Phase I Dose Escalation Safety and Pharmacokinetic Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients with Selected CD38+ Hemat...
    Medical condition: Haematological malignancy
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066476 Haematological malignancy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GR (Completed) GB (GB - no longer in EU/EEA) FI (Completed) BE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004001-32 Sponsor Protocol Number: EMN27 Start Date*: 2021-01-26
    Sponsor Name: European Myeloma Network – EMN
    Full Title: A phase 2 study of Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis
    Medical condition: relapsed or refractory AL amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10002022 Amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001700-15 Sponsor Protocol Number: MK-7684A-004 Start Date*: 2021-10-14
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of MK-7684A (MK-7684 [Vibostolimab] with MK-3475 [Pembrolizumab] Coformulation) in Participants with Relapsed or Refractory Hematolog...
    Medical condition: Relapsed/refractory hematological malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10066481 Hematological malignancy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) FR (Completed) ES (Ongoing) PL (Completed) IT (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000287-42 Sponsor Protocol Number: I15015 Start Date*: 2016-05-18
    Sponsor Name:CHU de Limoges
    Full Title: A Multicentre Open label Phase II study of Daratumumab in AL Amyloidosis Patients not in VGPR or Better
    Medical condition: AL Amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10005329 - Blood and lymphatic system disorders 10035227 Plasma cell neoplasms HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023076-10 Sponsor Protocol Number: CP14B015 Start Date*: 2011-02-28
    Sponsor Name:Geron Corporation
    Full Title: A Phase II Trial to Evaluate the Activity of Imetelstat (GRN163L) in Patients with Essential Thrombocythemia who Require Cytoreduction and Have Failed or Are Intolerant to Previous Therapy, or who ...
    Medical condition: Essential thrombocythemia
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015493 Essential thrombocythaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002554-23 Sponsor Protocol Number: BGB-A317-290-LTE1 Start Date*: 2020-12-09
    Sponsor Name:BeiGene, Ltd.
    Full Title: An Open-Label, Multicenter, Long-term Extension Study of Tislelizumab-Containing Treatment and/or Pamiparib-Containing Treatment in Patients With Advanced Malignancies
    Medical condition: solid tumors and hematological malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    21.1 100000004864 10066481 Hematological malignancy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002530-14 Sponsor Protocol Number: SI101-02 Start Date*: 2023-03-10
    Sponsor Name:SMART IMMUNE
    Full Title: An open-label, multi-center phase I/II study to assess the safety and the efficacy of SMART101 after -haploidentical peripheral blood stem transplantation with post-transplant cyclophosphamide in s...
    Medical condition: Patients with hematological malignancies requiring haploidentical peripheral blood stem transplantation with post-transplant cyclophosphamide
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10066481 Hematological malignancy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 17:16:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA